Piramal Pharma (NSE:PPLPHARMA) Construction In Progress: ₹7,992 Mil (As of Mar. 2026)


NSE:PPLPHARMA Piramal Pharma Ltd NSE:PPLPHARMA
53 GF Score
Price ₹175.95
GF Value ₹176.02
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Piramal Pharma Construction In Progress?

Piramal Pharma NSE:PPLPHARMA +4.55% 53 Construction In Progress is ₹7,992 Mil as of Mar. 2026. GuruFocus rates NSE:PPLPHARMA with a GF Score™ of 53/100 and a GF Value™ of ₹176.02 (Fairly Valued). The stock has 3 warning signs investors should review.

Piramal Pharma's quarterly construction in progress declined from Sep. 2025 (₹5,668 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹7,992 Mil).

Piramal Pharma's annual construction in progress declined from Mar. 2024 (₹5,657 Mil) to Mar. 2025 (₹4,891 Mil) but then increased from Mar. 2025 (₹4,891 Mil) to Mar. 2026 (₹7,992 Mil).

Piramal Pharma Construction In Progress Historical Data

* Premium members only.

The historical data trend for Piramal Pharma's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Piramal Pharma Construction In Progress Chart

Piramal Pharma Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Construction In Progress
Get a 7-Day Free Trial 6,731.50 8,529.30 5,657.00 4,891.20 7,991.70

Piramal Pharma Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,891.20 0.00 5,667.50 0.00 7,991.70
NSE:PPLPHARMA
53GF Score
Piramal Pharma Ltd NSE:PPLPHARMA
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Piramal Pharma Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ₹7,992 Mil mean?
Piramal Pharma (NSE:PPLPHARMA) has a Construction In Progress of ₹7,992 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Piramal Pharma and its competitors.
Is Piramal Pharma's Construction In Progress too high?
Piramal Pharma's current Construction In Progress is ₹7,992 Mil. Overall, Piramal Pharma has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's Construction In Progress compare to ZTS and UTHR?
Piramal Pharma's Construction In Progress of ₹7,992 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Piramal Pharma and its competitors. Piramal Pharma's current Construction In Progress is ₹7,992 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹176.02, compared to a current price of ₹175.95 — trading 0% below its estimated fair value. The current Construction In Progress is ₹7,992 Mil. Piramal Pharma's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current Construction In Progress is ₹7,992 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Piramal Pharma stock appears to be undervalued. The current stock price of ₹175.95 is trading 0% below its estimated GF Value™ of ₹176.02. GuruFocus considers Piramal Pharma to be Fairly Valued.

Key valuation signals for NSE:PPLPHARMA:

  • Construction In Progress: ₹7,992 Mil
  • GF Value™: ₹176.02 vs. price of ₹175.95 (0% below fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Piramal Pharma Business Description

Other Exchanges 543635:India
Address Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
53GF Score

Get the complete analysis for NSE:PPLPHARMA

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹175.95
Price
₹176.02
GF Value